EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog

Anoop Kapoor, Ankur Gupta, Nilay Desai, Hongshik Ahn

Prostate Cancer · 2011

DOI: 10.1155/2011/176164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Prostate Cancer, 2011. Verfasst von Anoop Kapoor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, University Hospital, SUNY, Stony Brook and VA Medical Center, Mail Code 111, 79 Middleville Road Northport, NY 11768, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Loss of bone density with androgen deprivation therapy for prostate cancer is well recognized. We assessed the effects of quarterly infusion of zoledronic acid on bone mineral density (BMD) and markers of bone turnover over a one-year period in men receiving gonadotropin-releasing hormone analog (GnRH-a) for prostate cancer.

Methods

41 subjects were randomly assigned to treatment with zoledronic acid (4 mg) IV infusion or placebo every 3 months. The primary endpoint was the change in the lumbar spine BMD after 12 months of treatment.

Results

The change in vertebral BMD in the zoledronic acid group () was significantly () greater than the change in the placebo group () as was the change in left femoral neck BMD ( for the zoledronic acid group versus for the placebo group). The decrease in biochemical markers of bone turnover was significantly () greater in the zoledronic acid group compared to the placebo group.

Conclusion

Quarterly infusion of zoledronic acid for 1 year improved vertebral and left femoral neck BMD with a decrease in bone turnover markers in men on GnRH-a treatment. Zoledronic acid treatment appears to be promising in men with low BMD receiving GnRH-a treatment.

Autor:innen und Institutionen

  • Division of Endocrinology, University Hospital, SUNY, Stony Brook and VA Medical Center, Mail Code 111, 79 Middleville Road Northport, NY 11768, USA.

Zitieren

APA

Kapoor, A., Gupta, A., Desai, N., & Ahn, H. (2011). Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog. Prostate Cancer. https://doi.org/10.1155/2011/176164

Vancouver

Kapoor A, Gupta A, Desai N, Ahn H. Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog. Prostate Cancer. 2011. doi:10.1155/2011/176164

BibTeX
@article{Kapoor2011,
  author = {Kapoor, Anoop and Gupta, Ankur and Desai, Nilay and Ahn, Hongshik},
  title = {Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog},
  journal = {Prostate Cancer},
  year = {2011},
  doi = {10.1155/2011/176164}
}
Kostenlos starten →